China Pharma Holdings Stock Performance
| CPHI Stock | USD 0.24 0.04 14.29% |
On a scale of 0 to 100, China Pharma holds a performance score of 6. The firm shows a Beta (market volatility) of 1.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, China Pharma will likely underperform. Please check China Pharma's semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether China Pharma's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in China Pharma Holdings are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady technical indicators, China Pharma demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2 M |
China |
China Pharma Relative Risk vs. Return Landscape
If you would invest 19.00 in China Pharma Holdings on December 24, 2024 and sell it today you would earn a total of 5.00 from holding China Pharma Holdings or generate 26.32% return on investment over 90 days. China Pharma Holdings is currently generating 0.8387% in daily expected returns and assumes 9.6999% risk (volatility on return distribution) over the 90 days horizon. In different words, 86% of stocks are less volatile than China, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
China Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for China Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as China Pharma Holdings, and traders can use it to determine the average amount a China Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0865
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CPHI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.7 actual daily | 86 86% of assets are less volatile |
Expected Return
| 0.84 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average China Pharma is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of China Pharma by adding it to a well-diversified portfolio.
China Pharma Fundamentals Growth
China Stock prices reflect investors' perceptions of the future prospects and financial health of China Pharma, and China Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on China Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 7.83 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Price To Earning | (0.89) X | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 0.82 X | ||||
| Revenue | 7.01 M | ||||
| EBITDA | 8.44 K | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 2.62 % | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | (699.69 K) | ||||
| Earnings Per Share | (0.69) X | ||||
| Total Asset | 16.47 M | ||||
| Retained Earnings | (39.29 M) | ||||
| Current Asset | 20.99 M | ||||
| Current Liabilities | 12.95 M | ||||
About China Pharma Performance
By evaluating China Pharma's fundamental ratios, stakeholders can gain valuable insights into China Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if China Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if China Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the Peoples Republic of China. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the Peoples Republic of China. China Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 236 people.Things to note about China Pharma Holdings performance evaluation
Checking the ongoing alerts about China Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for China Pharma Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| China Pharma is way too risky over 90 days horizon | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma appears to be risky and price may revert if volatility continues | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 51.0% of China Pharma shares are held by company insiders |
- Analyzing China Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether China Pharma's stock is overvalued or undervalued compared to its peers.
- Examining China Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating China Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of China Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of China Pharma's stock. These opinions can provide insight into China Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |